Novartis struggling to win payer coverage for $2.1M gene therapy Zolgensma: analysts

Only about one-third of the top 30 U.S. insurance companies have decided how to cover Novartis’ new $2.1 million gene therapy, Zolgensma, but analysts at one influential Wall Street firm are already worried. One reason? Their payer survey showed insurers are 'very unhappy' with Zolgensma's record-setting price.